Anteris Technologies Global Corp.
NGM: AVRLive Quote
📈 ZcoreAI Score
Our AI model analyzes Anteris Technologies Global Corp.'s price action across multiple timeframes using regression channels and statistical scoring.
Get AVR Z-Score →About Anteris Technologies Global Corp.
Healthcare
Medical Instruments & Supplies
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
📊 Fundamental Analysis
Anteris Technologies Global Corp. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -42.2% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -301.9%, which indicates that capital utilization is currently under pressure.
At a current price of $5.68, AVR currently sits at the 72nd percentile of its 52-week range (Range: $2.34 - $6.95).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$552.28M
Trailing P/E
--
Forward P/E
-5.86
Beta (5Y)
0.55
52W High
$6.95
52W Low
$2.34
Avg Volume
1.37M
Day High
Day Low